Welcome to our dedicated page for Tyra Biosciences news (Ticker: TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences stock.
Tyra Biosciences, Inc. (NASDAQ: TYRA) is a clinical-stage biotech leader developing targeted therapies for FGFR-driven cancers and skeletal disorders. This news hub provides investors and researchers with essential updates on TYRA-300 clinical progress, regulatory milestones, and strategic partnerships.
Key resources include trial result announcements, FDA designation updates, scientific conference presentations, and executive leadership insights. Our curated collection ensures access to verified information about the company's SNÅP platform advancements and pipeline expansion efforts.
Discover updates across three core areas: 1) Precision Oncology Developments (including urothelial carcinoma programs), 2) Skeletal Dysplasia Research (achondroplasia/hypochondroplasia studies), and 3) Technology Innovations (SNÅP platform enhancements). All content is vetted for accuracy and relevance to therapeutic development timelines.
Bookmark this page for real-time access to earnings call transcripts, peer-reviewed publication alerts, and partnership announcements. Monitor TYRA's progress in addressing drug resistance challenges through targeted FGFR3 inhibition strategies.
Tyra Biosciences (Nasdaq: TYRA) has announced a significant milestone in its BEACH301 Phase 2 clinical study, with the first child being dosed with dabogratinib (TYRA-300) for treating achondroplasia, the most common form of dwarfism.
Dabogratinib is positioned as the only oral FGFR3-selective inhibitor in clinical development for achondroplasia, which affects approximately 250,000 individuals worldwide. The drug targets the FGFR3 G380R mutation, present in 99% of achondroplasia cases. Initial results from the safety sentinel cohort are expected in 2H 2026.
The study aims to evaluate the safety and efficacy of this once-daily oral treatment, developed using TYRA's proprietary SNÅP platform, offering a potentially more accessible treatment option for children with achondroplasia.
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotech company specializing in Fibroblast Growth Factor Receptor (FGFR) precision medicines, has announced its participation in two upcoming investor events.
The company will participate in a fireside chat at the Virtual H.C. Wainwright "HCW@Home" series on August 21, 2025, at 11 AM ET. Additionally, management will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9 AM ET in New York, featuring a fireside chat and one-on-one investor meetings.
Webcasts of both events will be accessible through Tyra's investor relations website.
Tyra Biosciences (NASDAQ: TYRA) reported Q2 2025 financial results and significant progress in its clinical programs. The company maintains a strong financial position with $296.3 million in cash and equivalents, providing runway through 2027. Key developments include dosing the first patient in SURF302, a Phase 2 study evaluating dabogratinib for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC).
The company reported a net loss of $28.1 million for Q2 2025, with R&D expenses of $24.3 million and G&A expenses of $7.1 million. TYRA is advancing multiple clinical programs, including BEACH301 for achondroplasia, SURF431 for hepatocellular carcinoma, and SURF201 for intrahepatic cholangiocarcinoma. Important upcoming milestone includes topline data from SURF302 expected in 1H 2026.
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotech company specializing in Fibroblast Growth Factor Receptor (FGFR) precision medicines, has announced its participation in a virtual fireside chat at the UBS Biotech Management Live Call Series.
The event, focused on achondroplasia and growth disorders, will take place on July 25, 2025, at 11 am ET. Key participants include CEO Todd Harris, CMO Doug Warner, MD, and CFO Alan Fuhrman, with UBS SMID Cap Biotechnology Analyst Ellie Merle hosting the discussion.
Tyra Biosciences (Nasdaq: TYRA) has announced that its late-breaking abstract about TYRA-300 has been accepted for presentation at ENDO 2025, scheduled for July 12-15, 2025 in San Francisco. The poster presentation, titled "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia," will be presented by Dr. Jacqueline H. Starrett on July 13, 2025.
The presentation will be part of Session P70, focusing on bone and mineral metabolism, specifically rare bone and genetic disorders. The poster will be available on Tyra's investor relations website following the conference.
Tyra Biosciences (Nasdaq: TYRA) has initiated patient dosing in the Phase 2 SURF302 clinical trial of TYRA-300 for low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC). TYRA-300 is being developed as the first oral treatment for IR NMIBC and represents a potential first-in-class, FGFR3-selective inhibitor.
The SURF302 study (NCT06995677) will evaluate up to 90 participants across multiple U.S. sites, with patients randomized to receive either 50 mg or 60 mg once-daily doses. The trial's primary endpoint is the complete response (CR) rate at three months, with initial data expected in 1H 2026. Secondary endpoints include time to recurrence, duration of response, recurrence-free survival, progression-free survival, and safety measures.
Notably, TYRA-300 targets FGFR3, a gene mutated in approximately 70% of low-grade IR NMIBC cases. The drug is designed to minimize toxicities associated with inhibition of other FGFR types while remaining effective against FGFR3 gatekeeper mutations. The company also plans to evaluate TYRA-300 in pediatric achondroplasia through the BEACH301 Phase 2 study later this year.
[ "First patient dosed in Phase 2 SURF302 trial for IR NMIBC", "TYRA-300 is the only oral treatment in development for IR NMIBC", "Drug targets FGFR3 mutations present in ~70% of low-grade IR NMIBC cases", "Potential to reduce disease recurrence and surgical interventions", "Additional market opportunity in pediatric achondroplasia with BEACH301 Phase 2 study" ]Tyra Biosciences (NASDAQ: TYRA), a clinical-stage biotech company specializing in FGFR-targeted precision medicines, has announced its participation in three upcoming investor conferences. The company will attend the Bank of America Global Healthcare Conference (May 13-15) in Las Vegas, featuring a fireside chat on May 13 at 5:15 PM PT. Additionally, TYRA will participate in the Jefferies Global Healthcare Conference (June 3-5) and UBS Biotech 1x1 Symposium (June 24) in New York, both featuring one-on-one investor meetings. A webcast of the fireside chat will be accessible through TYRA's investor relations website.
Tyra Biosciences (NASDAQ: TYRA) reported its Q4 and full year 2024 financial results, highlighting significant progress in its precision medicine pipeline. The company ended 2024 with $341.4 million in cash and equivalents, providing runway through 2027.
Key developments include three FDA-cleared INDs for TYRA's precision small molecules, with TYRA-300 advancing to three Phase 2 studies: SURF302 for bladder cancer, BEACH301 for pediatric achondroplasia, and SURF301 for metastatic urothelial cancer. Notably, SURF301 showed promising interim results with 54.5% of patients achieving confirmed partial response.
Financial results show Q4 2024 net loss of $25.6 million compared to $22.8 million in Q4 2023. Full-year 2024 net loss was $86.5 million. R&D expenses increased to $80.1 million for 2024, up from $62.5 million in 2023.
Tyra Biosciences (NASDAQ: TYRA), a clinical-stage biotechnology company specializing in Fibroblast Growth Factor Receptor (FGFR) biology, has announced its participation in four major upcoming investor conferences in early 2025.
The company will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (February 11-12, virtual), the TD Cowen 45th Annual Healthcare Conference (March 3-5, Boston), the Jefferies Biotech on the Beach Summit (March 11-12, Miami), and the Barclays 27th Annual Global Healthcare Conference (March 11-13, Miami).
Management will engage in fireside chats and one-on-one investor meetings at most events, with presentations scheduled for February 12 at 2:00 PM ET (Oppenheimer), March 3 at 9:50 AM ET (TD Cowen), and March 12 at 8:30 AM ET (Barclays). Live and archived webcasts of the fireside chats will be accessible through TYRA's investor relations website.
FAQ
What is the current stock price of Tyra Biosciences (TYRA)?
What is the market cap of Tyra Biosciences (TYRA)?
